Biotech Values

[DewDiligence]

MON—…this arbitrarily timed push for 20% EPS growth has to be the result of management incentives.

There’s a simpler explanation—a 20% CAGR during the next three fiscal years is what MON must have to attain the previously stated goal of doubling non-GAAP EPS from FY2014 to FY2019.

See slide #5 at http://www.monsanto.com/investors/Documents/2015/2015-11-17_BIE/Financial-Translation-Courduroux_2015.11.18.pdf .